{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T12:24:51Z","timestamp":1787228691882,"version":"build-2736575974"},"reference-count":99,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The poliovirus receptor (CD155) is an emerging immune checkpoint molecule involved in the suppression of anti-tumor immunity. In ovarian cancer, CD155 is frequently overexpressed and interacts with receptors such as TIGIT, CD96, and CD226 to modulate the activity of T cells, NK cells, and dendritic cells. These interactions contribute to immune cell exhaustion, regulatory T cell expansion, and impaired cytotoxic responses, facilitating tumor immune evasion. Recent studies have revealed that CD155 expression is influenced by tumor metabolism, autophagy, and cytokine signaling. Therapeutic strategies targeting the CD155 axis\u2014through monoclonal antibodies, bispecific constructs, or engineered T\/NK cells\u2014are being actively explored and show promise in enhancing anti-tumor responses, particularly when combined with existing checkpoint inhibitors. This review provides a comprehensive overview of the structure, function, and receptor interactions of CD155 (PVR), with a particular focus on its immunoregulatory role in the ovarian tumor microenvironment. We discuss the signaling mechanisms of the TIGIT\/CD96\/CD226 axis, its impact on diverse immune cell populations, and the current landscape of therapeutic strategies targeting this pathway. Finally, we evaluate the potential of CD155 and its receptors as predictive biomarkers and therapeutic targets to overcome immune resistance and improve outcomes in ovarian cancer.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1903882","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:40:02Z","timestamp":1787226002000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The PVR-TIGIT\/CD96\/CD226 axis: a novel immune checkpoint target in ovarian cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Mingyao","family":"Huang","sequence":"first","affiliation":[{"name":"School of Basic Medicine Science, Key Laboratory of Translational Tumor Medicine in Fujian Province, Putian University","place":["Putian, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Zhang","sequence":"additional","affiliation":[{"name":"China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyan","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Nursing, The Fourth Hospital of Xianyou","place":["Putian, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, The Fourth Affiliated Hospital of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Fourth Affiliated Hospital of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat Med"},{"key":"B5","article-title":"Intratumoral T cells and survival in epithelial ovarian cancer","volume":"16","author":"Pautu","year":"2003","journal-title":"Natl Med J India"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0611533104","article-title":"Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer","volume":"104","author":"Hamanishi","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.107726","article-title":"Gut microbiota reshapes the TNBC immune microenvironment: Emerging immunotherapeutic strategies","volume":"215","author":"Huang","year":"2025","journal-title":"Pharmacol Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2025.2486519","article-title":"Gut microbiota in hepatocellular carcinoma immunotherapy: immune microenvironment remodeling and gut microbiota modification","volume":"17","author":"Huang","year":"2025","journal-title":"Gut Microbes"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/gut.49.2.236","article-title":"Overexpression of the CD155 gene in human colorectal carcinoma","volume":"49","author":"Masson","year":"2001","journal-title":"Gut"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-05-1890","article-title":"CD155\/PVR enhances glioma cell dispersal by regulating adhesion signaling and focal adhesion dynamics","volume":"65","author":"Sloan","year":"2005","journal-title":"Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2850","article-title":"The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions","volume":"15","author":"Chan","year":"2014","journal-title":"Nat Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2014.10.018","article-title":"The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function","volume":"26","author":"Johnston","year":"2014","journal-title":"Cancer Cell"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(89)90690-9","article-title":"Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily","volume":"56","author":"Mendelsohn","year":"1989","journal-title":"Cell"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1990.tb07520.x","article-title":"The poliovirus receptor protein is produced both as membrane-bound and secreted forms","volume":"9","author":"Koike","year":"1990","journal-title":"EMBO J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virusres.2017.09.001","article-title":"Poliovirus Receptor: More than a simple viral receptor","volume":"242","author":"Bowers","year":"2017","journal-title":"Virus Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/s0006-291x(03)01560-2","article-title":"Identification of secreted CD155 isoforms","volume":"309","author":"Baury","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.05.111","article-title":"Ligand stimulation of CD155alpha inhibits cell adhesion and enhances cell migration in fibroblasts","volume":"319","author":"Oda","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"B18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/ni.1674","article-title":"The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells","volume":"10","author":"Yu","year":"2009","journal-title":"Nat Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e004711","DOI":"10.1136\/jitc-2022-004711","article-title":"TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy","volume":"10","author":"Chiang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.04.689","article-title":"The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers","volume":"158","author":"Smazynski","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1815716116","article-title":"Binding mode of the side-by-side two-IgV molecule CD226\/DNAM-1 to its ligand CD155\/Necl-5","volume":"116","author":"Wang","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.5483\/bmbrep.2021.54.1.229","article-title":"Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy","volume":"54","author":"Jin","year":"2021","journal-title":"BMB Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.09.010","article-title":"CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8(+) T cells","volume":"53","author":"Braun","year":"2020","journal-title":"Immunity"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-023-00978-2","article-title":"CD8(+) CD226(high) T cells in liver metastases dictate the prognosis of colorectal cancer patients treated with chemotherapy and radical surgery","volume":"20","author":"Viot","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.148.8.2600","article-title":"Identification and molecular cloning of tactile. A novel human T cell activation antigen that is a member of the Ig gene superfamily","volume":"148","author":"Wang","year":"1992","journal-title":"J Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"10768","DOI":"10.1038\/s41598-020-66806-z","article-title":"CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma","volume":"10","author":"Liu","year":"2020","journal-title":"Sci Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01072","article-title":"Coming of age: CD96 emerges as modulator of immune responses","volume":"9","author":"Georgiev","year":"2018","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/eji.201948405","article-title":"CD96 functions as a co-stimulatory receptor to enhance CD8(+) T cell activation and effector responses","volume":"50","author":"Chiang","year":"2020","journal-title":"Eur J Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.3390\/ijms24021303","article-title":"CD96 as a potential immune regulator in cancers","volume":"24","author":"Feng","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.699895","article-title":"TIGIT, the next step towards successful combination immune checkpoint therapy in cancer","volume":"12","author":"Ge","year":"2021","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e000957","DOI":"10.1136\/jitc-2020-000957","article-title":"TIGIT in cancer immunotherapy","volume":"8","author":"Chauvin","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B33","doi-asserted-by":"crossref","DOI":"10.1111\/cei.13407","article-title":"TIGIT as an emerging immune checkpoint","volume":"200","author":"Harjunpaa","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-01-825265","article-title":"TIGIT immune checkpoint blockade restores CD8(+) T-cell immunity against multiple myeloma","volume":"132","author":"Guillerey","year":"2018","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-15-2626","article-title":"T-cell immunoglobulin and ITIM domain (TIGIT) associates with CD8+ T-cell exhaustion and poor clinical outcome in AML patients","volume":"22","author":"Kong","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-0296","article-title":"Single-cell RNA sequencing reveals the tissue architecture in human high-grade serous ovarian cancer","volume":"28","author":"Xu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12967-022-03480-x","article-title":"Blocking TIGIT\/CD155 signalling reverses CD8(+) T cell exhaustion and enhances the antitumor activity in cervical cancer","volume":"20","author":"Liu","year":"2022","journal-title":"J Transl Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-17-0381","article-title":"CD155T\/TIGIT signaling regulates CD8(+) T-cell metabolism and promotes tumor progression in human gastric cancer","volume":"77","author":"He","year":"2017","journal-title":"Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12964-023-01455-z","article-title":"The immune checkpoint TIGIT\/CD155 promotes the exhaustion of CD8 + T cells in TNBC through glucose metabolic reprogramming mediated by PI3K\/AKT\/mTOR signaling","volume":"22","author":"Huang","year":"2024","journal-title":"Cell Commun Signal"},{"key":"B40","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.cmet.2014.05.004","article-title":"The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function","volume":"20","author":"Macintyre","year":"2014","journal-title":"Cell Metab"},{"key":"B41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/imr.12845","article-title":"mTOR signaling at the crossroads of environmental signals and T-cell fate decisions","volume":"295","author":"Huang","year":"2020","journal-title":"Immunol Rev"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01887-3","article-title":"Macrophage-derived CCL23 upregulates expression of T-cell exhaustion markers in ovarian cancer","volume":"127","author":"Kamat","year":"2022","journal-title":"Br J Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2020.1843247","article-title":"TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1\/TIGIT\/CD96 checkpoint molecules in ovarian cancer","volume":"9","author":"Maas","year":"2020","journal-title":"Oncoimmunology"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107705","article-title":"Artesunate-induced ATG5-related autophagy enhances the cytotoxicity of NK92 cells on endometrial cancer cells via interactions between CD155 and CD226\/TIGIT","volume":"97","author":"Zhang","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"8775","DOI":"10.3390\/ijms25168775","article-title":"Uncovering the expression pattern of the costimulatory receptors ICOS, 4-1BB, and OX-40 in exhausted peripheral and tumor-infiltrating natural killer cells from patients with cervical cancer","volume":"25","author":"Rojas-Diaz","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B46","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.omto.2020.02.001","article-title":"NK cells augment oncolytic adenovirus cytotoxicity in ovarian cancer","volume":"16","author":"Leung","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-023-01167-5","article-title":"A novel autophagy-related gene signature associated with prognosis and immune microenvironment in ovarian cancer","volume":"16","author":"Yang","year":"2023","journal-title":"J Ovarian Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2012.141","article-title":"Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells","volume":"20","author":"Liu","year":"2013","journal-title":"Cell Death Differ"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m114.572420","article-title":"T-cell immunoglobulin and ITIM domain (TIGIT) receptor\/poliovirus receptor (PVR) ligand engagement suppresses interferon-gamma production of natural killer cells via beta-arrestin 2-mediated negative signaling","volume":"289","author":"Li","year":"2014","journal-title":"J Biol Chem"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2016.151","article-title":"Regulatory T cells in cancer immunotherapy","volume":"27","author":"Tanaka","year":"2017","journal-title":"Cell Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.02.012","article-title":"Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses","volume":"40","author":"Joller","year":"2014","journal-title":"Immunity"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2976","article-title":"TIGIT enhances CD4(+) regulatory T-cell response and mediates immune suppression in a murine ovarian cancer model","volume":"9","author":"Chen","year":"2020","journal-title":"Cancer Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2117065119","article-title":"Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155\/TIGIT axis","volume":"119","author":"Ozmadenci","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402381","article-title":"Divergent phenotypes of human regulatory T cells expressing the receptors TIGIT and CD226","volume":"195","author":"Fuhrman","year":"2015","journal-title":"J Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(01)00456-1","article-title":"Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity","volume":"106","author":"Liu","year":"2001","journal-title":"Cell"},{"key":"B56","doi-asserted-by":"crossref","DOI":"10.1016\/S0092-8674(01)00449-4","article-title":"Dendritic cells: specialized and regulated antigen processing machines","volume":"106","author":"Mellman","year":"2001","journal-title":"Cell"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2017.06.037","article-title":"CD155 blockade improves survival in experimental sepsis by reversing dendritic cell dysfunction","volume":"490","author":"Meng","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1250258","article-title":"Immunosuppressive M2 TAMs represent a promising target population to enhance phagocytosis of ovarian cancer cells in vitro","volume":"14","author":"Brauneck","year":"2023","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(00)70060-4","article-title":"DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes","volume":"4","author":"Shibuya","year":"1996","journal-title":"Immunity"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(00)80136-3","article-title":"Physical and functional association of LFA-1 with DNAM-1 adhesion molecule","volume":"11","author":"Shibuya","year":"1999","journal-title":"Immunity"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20150792","article-title":"DNAM-1 controls NK cell activation via an ITT-like motif","volume":"212","author":"Zhang","year":"2015","journal-title":"J Exp Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1103627","article-title":"The TIGIT\/CD226 axis regulates human T cell function","volume":"188","author":"Lozano","year":"2012","journal-title":"J Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2016.1196308","article-title":"Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing","volume":"5","author":"Kearney","year":"2016","journal-title":"Oncoimmunology"},{"key":"B64","doi-asserted-by":"crossref","DOI":"10.1158\/2326-6066.CIR-18-0022","article-title":"NK cell education in tumor immune surveillance: DNAM-1\/KIR receptor ratios as predictive biomarkers for solid tumor outcome","volume":"6","author":"Guillamon","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2007.02660.x","article-title":"Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125)","volume":"122","author":"Belisle","year":"2007","journal-title":"Immunology"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022842","article-title":"Human tumour immune evasion via TGF-beta blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity","volume":"6","author":"Wilson","year":"2011","journal-title":"PloS One"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211538","article-title":"Suppression of natural killer cell NKG2D and CD226 anti-tumour cascades by platelet cloaked cancer cells: Implications for the metastatic cascade","volume":"14","author":"Cluxton","year":"2019","journal-title":"PloS One"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2121-4","article-title":"An IL-15 superagonist\/IL-15Ralpha fusion complex protects and rescues NK cell-cytotoxic function from TGF-beta1-mediated immunosuppression","volume":"67","author":"Fujii","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B69","doi-asserted-by":"publisher","first-page":"15177","DOI":"10.3390\/ijms232315177","article-title":"miR-221-5p and miR-186-5p are the critical bladder cancer derived exosomal miRNAs in natural killer cell dysfunction","volume":"23","author":"Huyan","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20081752","article-title":"DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors","volume":"205","author":"Gilfillan","year":"2008","journal-title":"J Exp Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.clim.2017.08.021","article-title":"CD8(+)T cells expressing both PD-1 and TIGIT but not CD226 are dysfunctional in acute myeloid leukemia (AML) patients","volume":"190","author":"Wang","year":"2018","journal-title":"Clin Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12518","article-title":"TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy","volume":"276","author":"Dougall","year":"2017","journal-title":"Immunol Rev"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.7.3994","article-title":"Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155)","volume":"172","author":"Fuchs","year":"2004","journal-title":"J Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.634617","article-title":"CD96 correlates with immune infiltration and impacts patient prognosis: A pan-cancer analysis","volume":"11","author":"Ye","year":"2021","journal-title":"Front Oncol"},{"key":"B75","article-title":"Tumor cell-intrinsic CD96 mediates chemoresistance and cancer stemness by regulating mitochondrial fatty acid beta-oxidation","volume":"10","author":"Li","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxh059","article-title":"Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2\/CD112)","volume":"16","author":"Tahara-Hanaoka","year":"2004","journal-title":"Int Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2016.10.002","article-title":"TIGIT: A key inhibitor of the cancer immunity cycle","volume":"38","author":"Manieri","year":"2017","journal-title":"Trends Immunol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"922","DOI":"10.3390\/ijms21030922","article-title":"CD155: A multi-functional molecule in tumor progression","volume":"21","author":"Molfetta","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-018-0683-9","article-title":"The bispecific anti-CD3 x anti-CD155 antibody mediates T cell immunotherapy for human prostate cancer","volume":"37","author":"Zhao","year":"2019","journal-title":"Invest New Drugs"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-025-01529-4","article-title":"Bispecific antibody targeting CD155 mediates T-cell immunotherapy against human gynecological Malignancies","volume":"43","author":"Ma","year":"2025","journal-title":"Invest New Drugs"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.26435","article-title":"Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy","volume":"233","author":"Nasiri","year":"2018","journal-title":"J Cell Physiol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.2174\/1574884712666180802095521","article-title":"Antibody-drug conjugates: A review on the epitome of targeted anti-cancer therapy","volume":"13","author":"Hasan","year":"2018","journal-title":"Curr Clin Pharmacol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"B84","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00262-024-03867-3","article-title":"Overcoming immunosuppression in cancer: How ketogenic diets boost immune checkpoint blockade","volume":"74","author":"Stefan","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B85","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13045-020-00913-2","article-title":"CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma","volume":"13","author":"Lupo","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s13046-021-02068-5","article-title":"Poliovirus receptor (PVR)-like protein cosignaling network: New opportunities for cancer immunotherapy","volume":"40","author":"Wu","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01825","article-title":"Natural killer cell-based immunotherapy in gynecologic Malignancy: A review","volume":"8","author":"Uppendahl","year":"2017","journal-title":"Front Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1097\/gco.0000000000000433","article-title":"Cell-based immunotherapy in gynecologic Malignancies","volume":"31","author":"Schaar","year":"2019","journal-title":"Curr Opin Obstet Gynecol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.88539","article-title":"NK-92MI cells engineered with anti-claudin-6 chimeric antigen receptors in immunotherapy for ovarian cancer","volume":"20","author":"Li","year":"2024","journal-title":"Int J Biol Sci"},{"key":"B90","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","article-title":"Exploring the NK cell platform for cancer immunotherapy","volume":"18","author":"Myers","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B91","doi-asserted-by":"crossref","DOI":"10.1002\/eji.201243072","article-title":"Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR","volume":"43","author":"Stanietsky","year":"2013","journal-title":"Eur J Immunol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-15-0944","article-title":"Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy","volume":"6","author":"Blake","year":"2016","journal-title":"Cancer Discov"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2018.1424677","article-title":"CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity","volume":"7","author":"Roman Aguilera","year":"2018","journal-title":"Oncoimmunology"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2018.03.014","article-title":"Engineering T cells for adoptive therapy: Outsmarting the tumor","volume":"51","author":"Kunert","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.618387","article-title":"Befriending the hostile tumor microenvironment in CAR T-cell therapy","volume":"11","author":"Lindo","year":"2020","journal-title":"Front Immunol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"11781","DOI":"10.3390\/ijms222111781","article-title":"Cell therapy for colorectal cancer: The promise of chimeric antigen receptor (CAR)-T cells","volume":"22","author":"Aparicio","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B97","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12943-018-0840-y","article-title":"Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy","volume":"17","author":"Pang","year":"2018","journal-title":"Mol Cancer"},{"key":"B98","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s11095-018-2436-z","article-title":"Chimeric antigen receptor T-cells (CAR T-cells) for cancer immunotherapy - Moving target for industry","volume":"35","author":"Salmikangas","year":"2018","journal-title":"Pharm Res"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0132-0","article-title":"Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity","volume":"19","author":"Zhang","year":"2018","journal-title":"Nat Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1903882\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:40:04Z","timestamp":1787226004000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1903882\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":99,"alternative-id":["10.3389\/fimmu.2026.1903882"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1903882","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"article-number":"1903882"}}